https://nordiclifescience.org/fda-approval-astrazenecas-calquence/
FDA approval for AstraZeneca's Calquence - NLS
Nov 1, 2017 - AstraZeneca and its haematology research and development centre of excellence, Acerta Pharma, has announced that the FDA has granted accelerated approval to...
fda approvalastrazenecacalquencenls
https://www.pharmaceutical-technology.com/data-insights/calquence-astrazeneca-nodal-marginal-zone-b-cell-lymphoma-likelihood-of-approval/
Calquence by AstraZeneca for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval
Dec 30, 2024 - Calquence is under clinical development by AstraZeneca and currently in Phase II for Nodal Marginal Zone B-Cell Lymphoma.
zone bcalquenceastrazenecanodalmarginal
https://www.medsinfo.com.au/product-information/document/Calquence_tablets_PI?drug_id=18980&documenttype=pi
Product Information - Calquence tablets
View or download Product Information (PI) document for Calquence tablets
product informationcalquencetablets
https://contratos-publicos.comunidad.madrid/contrato-publico/suministro-medicamento-exclusivo-acalabrutinib-calquence
SUMINISTRO DE MEDICAMENTO EXCLUSIVO ACALABRUTINIB (CALQUENCE)
SUMINISTRO DE MEDICAMENTO EXCLUSIVO ACALABRUTINIB (CALQUENCE)
suministrodemedicamentoexclusivocalquence
https://mddetails.com/downloads/calquence-2018-report/
Calquence 2018 report | MDDetails
calquencereport
https://pharmaphorum.com/news/amplify-results-dial-calquences-potential-cll
AMPLIFY results dial up Calquence's potential in CLL | pharmaphorum
AstraZeneca's Calquence hits the mark in the AMPLIFY combination trial in CLL, which could unlock a blockbuster opportunity for the BTK inhibitor.
dial upamplifyresultscalquencepotential